Novo Holdings

Sparrow Quantum Aps. is a Danish company focused on advancing quantum technology through the development of light-matter interfaces. It specializes in creating deterministic single-photon sources, which are essential for various quantum applications. The company boasts the highest efficiency in on-chip single-photon sources globally, characterized by superior photon purity, indistinguishability, and outcoupling capabilities. This innovative technology is the culmination of over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which Sparrow Quantum holds exclusive licenses to key patents. By leveraging self-assembled quantum dots integrated with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interaction, providing clients with advanced solutions for their quantum technology needs.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Biocomposites Limited specializes in the development, manufacturing, and distribution of calcium compound devices aimed at regenerating and repairing bone and soft tissue. Founded in 1996 and located in Keele, United Kingdom, the company offers a range of innovative products including STIMULAN, a pharmaceutical-grade calcium sulfate for infection management; geneX, an absorbable synthetic bone graft material that accelerates bone growth; and Allogran-R, a calcium phosphate bone substitute providing an osteoconductive scaffold. Additionally, Biocomposites produces Bilok, a synthetic calcium composite used in ligament reconstruction, and Biosteon, a technology designed to enhance implant and bone integration. Their products are utilized in various medical applications, including musculoskeletal infections, bone and joint trauma, spine surgery, and sports injuries, enabling healthcare providers to deliver effective treatment solutions.

Commit Biologics is a biotechnology research company based in Aarhus, Denmark, established in 2021. The company specializes in developing an innovative immunotherapy platform aimed at treating various types of cancer. This platform utilizes bispecific domain antibodies to effectively target and eliminate tumor cells. Furthermore, it incorporates modular technology that enhances its ability to engage the body's innate immune response, thereby activating the complement component of the immune system. This approach not only focuses on cancer treatment but also has potential applications in addressing autoimmune diseases.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

Single Use Support GmbH, founded in 2015 and headquartered in Kufstein, Austria, specializes in the manufacturing of heavy-duty single-use plastic containers and packaging products designed for the transportation of liquids, particularly in the pharmaceuticals and biopharma sectors. The company develops innovative bulk filling systems, including BULK.STREAM and RoSS.FILL, to enhance fluid logistics processes and minimize the risk of leakage or bio-contamination. By providing tailored packaging solutions, Single Use Support aims to improve the efficiency and safety of liquid transport, addressing the specific needs of its clients in the pharmaceutical industry.

Commit Biologics is a biotechnology research company based in Aarhus, Denmark, established in 2021. The company specializes in developing an innovative immunotherapy platform aimed at treating various types of cancer. This platform utilizes bispecific domain antibodies to effectively target and eliminate tumor cells. Furthermore, it incorporates modular technology that enhances its ability to engage the body's innate immune response, thereby activating the complement component of the immune system. This approach not only focuses on cancer treatment but also has potential applications in addressing autoimmune diseases.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, focused on developing medical treatments for atrial fibrillation (AF), the most prevalent type of cardiac arrhythmia. Founded in 2011, Acesion Pharma specializes in creating SK channel inhibitors that aim to provide safe and tolerable chronic treatments for AF. These drugs work by inhibiting specific ion channels in heart cells, which are crucial for generating the electrical signals that regulate the heart's rhythm. The company's goal is to offer effective solutions for preventing the recurrence of atrial fibrillation and maintaining normal heart rhythm, thereby improving the quality of life for patients affected by this condition.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

AMSilk GmbH is a Munich-based company that specializes in the production of spider silk proteins and other biomaterials for a variety of industrial applications. Founded in 2008, AMSilk manufactures high-quality silk biopolymers that serve diverse sectors, including pharmaceuticals, cosmetics, and technical textiles. Its product offerings include BioShield-S1, a non-immunogenic spider silk film for protective coatings, as well as biosteel spider silk fibers. The company also develops a range of wound care products and surgical applications, such as the SanaSilk durable skin barrier. Additionally, AMSilk provides spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Utilizing a patented biotechnological process, AMSilk's materials are fully biodegradable under aerobic and marine conditions, promoting sustainability in various applications. The company collaborates with partners like Gruschwitz Textilwerke AG to enhance its product offerings.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Chromologics is a Danish biotechnology company specializing in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company has created a fermentation-derived platform for producing novel bio-based color pigments. These colorants are designed to offer optimal stability in terms of pH and temperature, making them suitable for a wide range of food products. Chromologics aims to provide food producers with sustainable alternatives to traditional colorants, such as carmine, thereby enhancing the natural appeal of food while supporting a shift towards more environmentally friendly practices in the food industry.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.

Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create biocatalysts at an accelerated pace and efficiency, using a patent-pending high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia facilitates more sustainable and cost-effective manufacturing processes for its industrial partners. The company operates from the Novo Nordisk Foundation Center for Biosustainability in Hørsholm.

Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Chromologics is a Danish biotechnology company specializing in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company has created a fermentation-derived platform for producing novel bio-based color pigments. These colorants are designed to offer optimal stability in terms of pH and temperature, making them suitable for a wide range of food products. Chromologics aims to provide food producers with sustainable alternatives to traditional colorants, such as carmine, thereby enhancing the natural appeal of food while supporting a shift towards more environmentally friendly practices in the food industry.

AMSilk GmbH is a Munich-based company that specializes in the production of spider silk proteins and other biomaterials for a variety of industrial applications. Founded in 2008, AMSilk manufactures high-quality silk biopolymers that serve diverse sectors, including pharmaceuticals, cosmetics, and technical textiles. Its product offerings include BioShield-S1, a non-immunogenic spider silk film for protective coatings, as well as biosteel spider silk fibers. The company also develops a range of wound care products and surgical applications, such as the SanaSilk durable skin barrier. Additionally, AMSilk provides spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Utilizing a patented biotechnological process, AMSilk's materials are fully biodegradable under aerobic and marine conditions, promoting sustainability in various applications. The company collaborates with partners like Gruschwitz Textilwerke AG to enhance its product offerings.

The Renewable Energy Partnership is a partnership between Novo Holdings, Sampension, and European Energy with the intention to buy land for the construction of solar and wind farms in Denmark and Sweden. The three partners will provide DKK 650 million (approx. EUR 87 million) with the possibility of investments of up to DKK 1.5 billion (approx. EUR 200 million) through debt financing. This will significantly increase investments in the green transition in Denmark and Sweden.

Deep Branch Biotechnology Ltd., founded in 2018 and based in Nottingham, United Kingdom, specializes in carbon recycling services aimed at creating sustainable food ingredients. The company employs a proprietary gas fermentation platform that utilizes clean and renewable carbon and energy sources to produce bio-based products for the food and feed markets. By focusing on customer-driven research and development, Deep Branch rapidly delivers high-quality ingredients while collaborating with local providers to ensure sustainable input supplies and support local economies. Its approach includes integrating with carbon dioxide suppliers to deploy its technology efficiently, contributing to a reduction in carbon footprints by up to 60% compared to traditional alternatives. This innovative model allows Deep Branch to create locally-produced ingredients that require no arable land and minimal water, effectively addressing climate change and biodiversity loss while ensuring that consumers do not have to compromise on nutrition or quality.

ZELP Ltd. is a London-based company established in 2017 that focuses on developing innovative wearable technology aimed at reducing methane emissions from livestock. The company's primary product is a device that oxidizes methane into carbon dioxide, thereby mitigating the environmental impact of the livestock industry. In addition to its emission-reducing capabilities, the device includes features such as geolocation, heat detection, early disease detection, and emission frequency monitoring. These functionalities assist farmers in managing their livestock more effectively while contributing to sustainability in agriculture.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

The Protein Brewery B.V. is a high-tech company based in Breda, Netherlands, focused on the development, manufacturing, and commercialization of animal-free protein products. Founded in 2019 as a spin-out from BioscienZ, the company specializes in producing Fermotein, a fungi-based protein created through advanced fermentation technologies. This innovative approach not only replaces traditional animal-based proteins but also utilizes significantly less land and water, ensuring a more sustainable production process. The Protein Brewery's products offer consumers protein-rich foods that contain all essential amino acids, vitamins, and minerals necessary for a healthy and balanced diet, all while maintaining taste and performance.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on innovative cancer treatments. Founded in 2016, it specializes in the development of proprietary bispecific antibodies that engage gamma-delta T cells, aiming to harness the immune system's power to target and destroy tumor cells. The company's platform creates next-generation γδ T cell engaging antibodies designed for both hematological and solid tumors, emphasizing safety, potency, and cost-effectiveness in its biopharmaceuticals. By combining immune recruiting and activating functionalities, Lava Therapeutics seeks to transform cancer therapy and improve patient outcomes.

Chromologics is a Danish biotechnology company specializing in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company has created a fermentation-derived platform for producing novel bio-based color pigments. These colorants are designed to offer optimal stability in terms of pH and temperature, making them suitable for a wide range of food products. Chromologics aims to provide food producers with sustainable alternatives to traditional colorants, such as carmine, thereby enhancing the natural appeal of food while supporting a shift towards more environmentally friendly practices in the food industry.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Verona Pharma plc is a clinical-stage biopharmaceutical company based in London, dedicated to developing and commercializing innovative therapies for respiratory diseases with significant unmet medical needs. Founded in 2005, the company primarily focuses on its lead product candidate, ensifentrine, an inhaled dual inhibitor of phosphodiesterase enzymes 3 and 4, which functions as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with additional formulations including a dry powder inhaler and a pressurized metered-dose inhaler also under development. In addition to COPD, Verona Pharma is exploring the use of ensifentrine for other respiratory conditions, including cystic fibrosis and asthma, thereby aiming to enhance the health and quality of life for patients suffering from these chronic disorders.

Reapplix ApS is a research and development company based in Birkerod, Denmark, founded in 2008. The company specializes in identifying and isolating blood-derived proteins that enhance wound healing, specifically for patients with chronic wounds. Reapplix designs and manufactures a tissue regeneration device that offers biological treatment for diabetic foot ulcers. Its platform facilitates evidence-based biological wound therapy, utilizing the patient's own blood to provide autologous active cell therapy, thereby empowering hospitals to support patients in their healing processes.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

NodThera Limited is a biotechnology company engaged in the research and development of novel inhibitors targeting the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. Founded in 2016 and headquartered in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and a corporate office in Lexington, Massachusetts, NodThera focuses on creating therapies for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company's drug development pipeline includes potent and selective NLRP3 inflammasome inhibitors designed to reduce pro-inflammatory cytokines associated with chronic inflammation, thereby enhancing treatment options for patients suffering from these chronic diseases.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Reapplix ApS is a research and development company based in Birkerod, Denmark, founded in 2008. The company specializes in identifying and isolating blood-derived proteins that enhance wound healing, specifically for patients with chronic wounds. Reapplix designs and manufactures a tissue regeneration device that offers biological treatment for diabetic foot ulcers. Its platform facilitates evidence-based biological wound therapy, utilizing the patient's own blood to provide autologous active cell therapy, thereby empowering hospitals to support patients in their healing processes.

Stipe Therapeutics is a biopharmaceutical company based in Aarhus C, Denmark, founded in 2018. The company specializes in developing peptide therapeutics aimed at eliminating tumors and combating cancer by harnessing the innate immune system. Stipe Therapeutics focuses on creating first-in-class drugs that target intracellular protein-protein interactions within the STING Pathway, which plays a crucial role in innate immunity and the regulation of tumorigenesis and autoimmune disorders. Through the identification and validation of compounds that sensitize the STING pathway, Stipe Therapeutics aims to modulate the tumor microenvironment, thereby enhancing the body's anti-tumoral responses and improving treatment outcomes for cancer patients.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in the research, development, and manufacturing of lentiviral vector and cell therapy products for various diseases. The company operates through two main segments: Platform and Product. Its LentiVector platform technology enables the integration of therapeutic genes into non-dividing cells, making it suitable for treating conditions affecting the brain and eyes. Oxford BioMedica's product pipeline includes several candidates in various stages of development, targeting diseases such as hematological tumors, age-related macular degeneration, and central nervous system disorders. Additionally, the company has established partnerships with notable firms like Novartis and Bristol Myers Squibb to advance its therapeutic offerings. Oxford BioMedica also focuses on growing its bioprocessing services, leveraging its technologies to provide revenue-generating solutions for third-party clients, while continuing to innovate in gene and cell therapy. Founded in 1995, the company has positioned itself as a leader in the field of gene therapy, addressing unmet medical needs through its advanced therapeutic candidates.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in the research, development, and manufacturing of lentiviral vector and cell therapy products for various diseases. The company operates through two main segments: Platform and Product. Its LentiVector platform technology enables the integration of therapeutic genes into non-dividing cells, making it suitable for treating conditions affecting the brain and eyes. Oxford BioMedica's product pipeline includes several candidates in various stages of development, targeting diseases such as hematological tumors, age-related macular degeneration, and central nervous system disorders. Additionally, the company has established partnerships with notable firms like Novartis and Bristol Myers Squibb to advance its therapeutic offerings. Oxford BioMedica also focuses on growing its bioprocessing services, leveraging its technologies to provide revenue-generating solutions for third-party clients, while continuing to innovate in gene and cell therapy. Founded in 1995, the company has positioned itself as a leader in the field of gene therapy, addressing unmet medical needs through its advanced therapeutic candidates.

Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Inthera Bioscience AG is a private biopharmaceutical company based in Schlieren, Switzerland, founded in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera Bioscience leverages its proprietary technology platform to create inhibitors that block aberrant protein-protein interactions, which play a critical role in cancer cell signaling. By focusing on these intracellular interactions, the company seeks to improve treatment outcomes for patients with cancer through the development of novel oral agents.

Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create biocatalysts at an accelerated pace and efficiency, using a patent-pending high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia facilitates more sustainable and cost-effective manufacturing processes for its industrial partners. The company operates from the Novo Nordisk Foundation Center for Biosustainability in Hørsholm.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

Inthera Bioscience AG is a private biopharmaceutical company based in Schlieren, Switzerland, founded in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera Bioscience leverages its proprietary technology platform to create inhibitors that block aberrant protein-protein interactions, which play a critical role in cancer cell signaling. By focusing on these intracellular interactions, the company seeks to improve treatment outcomes for patients with cancer through the development of novel oral agents.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Macrophage Pharma Limited is an immuno-oncology company based in Berkhamsted, United Kingdom, focused on the discovery and development of innovative therapies aimed at enhancing anti-tumour immune responses. Established in 2014, the company utilizes a specialized technology platform that selectively delivers small molecule drugs to tumour-associated macrophages. This targeted approach aims to activate the body’s natural immune system, empowering it to combat cancer more effectively. By focusing on the interaction between immune cells and tumours, Macrophage Pharma seeks to develop novel treatments that improve patient outcomes in cancer therapy.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, focused on developing medical treatments for atrial fibrillation (AF), the most prevalent type of cardiac arrhythmia. Founded in 2011, Acesion Pharma specializes in creating SK channel inhibitors that aim to provide safe and tolerable chronic treatments for AF. These drugs work by inhibiting specific ion channels in heart cells, which are crucial for generating the electrical signals that regulate the heart's rhythm. The company's goal is to offer effective solutions for preventing the recurrence of atrial fibrillation and maintaining normal heart rhythm, thereby improving the quality of life for patients affected by this condition.

Reapplix ApS is a research and development company based in Birkerod, Denmark, founded in 2008. The company specializes in identifying and isolating blood-derived proteins that enhance wound healing, specifically for patients with chronic wounds. Reapplix designs and manufactures a tissue regeneration device that offers biological treatment for diabetic foot ulcers. Its platform facilitates evidence-based biological wound therapy, utilizing the patient's own blood to provide autologous active cell therapy, thereby empowering hospitals to support patients in their healing processes.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Verona Pharma plc is a clinical-stage biopharmaceutical company based in London, dedicated to developing and commercializing innovative therapies for respiratory diseases with significant unmet medical needs. Founded in 2005, the company primarily focuses on its lead product candidate, ensifentrine, an inhaled dual inhibitor of phosphodiesterase enzymes 3 and 4, which functions as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with additional formulations including a dry powder inhaler and a pressurized metered-dose inhaler also under development. In addition to COPD, Verona Pharma is exploring the use of ensifentrine for other respiratory conditions, including cystic fibrosis and asthma, thereby aiming to enhance the health and quality of life for patients suffering from these chronic disorders.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, focused on developing medical treatments for atrial fibrillation (AF), the most prevalent type of cardiac arrhythmia. Founded in 2011, Acesion Pharma specializes in creating SK channel inhibitors that aim to provide safe and tolerable chronic treatments for AF. These drugs work by inhibiting specific ion channels in heart cells, which are crucial for generating the electrical signals that regulate the heart's rhythm. The company's goal is to offer effective solutions for preventing the recurrence of atrial fibrillation and maintaining normal heart rhythm, thereby improving the quality of life for patients affected by this condition.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Inthera Bioscience AG is a private biopharmaceutical company based in Schlieren, Switzerland, founded in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera Bioscience leverages its proprietary technology platform to create inhibitors that block aberrant protein-protein interactions, which play a critical role in cancer cell signaling. By focusing on these intracellular interactions, the company seeks to improve treatment outcomes for patients with cancer through the development of novel oral agents.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions affecting women. Its key products in development include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and heavy menstrual bleeding associated with uterine fibroids. ObsEva is also working on OBE022, a once-daily oral prostaglandin F2α receptor antagonist designed for managing preterm labor between 24 and 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily within the Swiss market while targeting global solutions for women's reproductive health needs.

Kanyos Bio is focused on creating antigen-specific immune tolerance therapies aimed at treating type 1 diabetes and celiac disease. The company was established to develop disease-modifying treatments that specifically target immune cells responsible for damaging the intestine, while preserving the function of other immune cells. This targeted approach allows for more precise treatment options, potentially leading to improved outcomes for patients. Kanyos Bio's technology has its roots at the École Polytechnique Fédérale Lausanne in Switzerland, and it collaborates with its sister company, Anokion, along with Astellas Pharma to advance its innovations in immunotherapy. Through this collaboration, Kanyos Bio seeks to leverage expertise in immunotechnology and clinical translation to bring effective therapies to market for individuals suffering from these autoimmune conditions.

Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create biocatalysts at an accelerated pace and efficiency, using a patent-pending high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia facilitates more sustainable and cost-effective manufacturing processes for its industrial partners. The company operates from the Novo Nordisk Foundation Center for Biosustainability in Hørsholm.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, focused on developing medical treatments for atrial fibrillation (AF), the most prevalent type of cardiac arrhythmia. Founded in 2011, Acesion Pharma specializes in creating SK channel inhibitors that aim to provide safe and tolerable chronic treatments for AF. These drugs work by inhibiting specific ion channels in heart cells, which are crucial for generating the electrical signals that regulate the heart's rhythm. The company's goal is to offer effective solutions for preventing the recurrence of atrial fibrillation and maintaining normal heart rhythm, thereby improving the quality of life for patients affected by this condition.

Adaptimmune Therapeutics, established in 2008, is a UK-based clinical-stage biopharmaceutical company specializing in novel cell therapies for solid tumor patients. Its core technology, the Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform, enables the identification of cancer targets and the development of affinity-enhanced T-cell receptors. Adaptimmune's pipeline includes several SPEAR T-cell therapies in phase I clinical trials, targeting various solid tumors such as urothelial, melanoma, and non-small cell lung cancer. The company has strategic collaborations with GSK, Noile-Immune Biotech, and Universal Cells, Inc. to advance its T-cell therapies.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Acacia Pharma Group plc, established in 2007, is a UK-based hospital pharmaceutical company specializing in the discovery, development, and commercialization of products for patients undergoing surgery, invasive procedures, or cancer chemotherapy. Its primary focus is on treating and preventing post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Acacia Pharma's lead product, BARHEMSYS, is an intravenous amisulpride for PONV treatment and prophylaxis. Other key products include APD403, an intravenous and oral amisulpride for CINV, and BYFAVO, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic for use in invasive medical procedures. These products primarily serve anesthesiologists and oncologists.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions affecting women. Its key products in development include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and heavy menstrual bleeding associated with uterine fibroids. ObsEva is also working on OBE022, a once-daily oral prostaglandin F2α receptor antagonist designed for managing preterm labor between 24 and 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily within the Swiss market while targeting global solutions for women's reproductive health needs.

Xellia Pharmaceuticals ApS is a specialty pharmaceutical company headquartered in Copenhagen, Denmark, with additional facilities in Budapest, Hungary; Taizhou, China; and Raleigh, North Carolina. Founded in 1959, Xellia focuses on the development, manufacture, and supply of anti-infective products, specifically targeting serious bacterial and antibiotic-resistant infections, as well as certain fungal diseases. The company is recognized as a leading supplier of fermented and semi-synthetic active pharmaceutical ingredients (APIs) and finished dosage forms (FDF), with a particular emphasis on its flagship products, Vancomycin and Colistimethate Sodium. Xellia serves over 700 customers in more than 70 countries and offers a range of services, including antibiotic contract manufacturing, custom synthesis for clinical trials, and the development of innovative delivery systems for injectable, topical, and inhaled administration. The company's manufacturing facilities adhere to current Good Manufacturing Practice (cGMP) standards and are approved by relevant regulatory authorities, including the US Food and Drug Administration. With a workforce of over 850 employees, Xellia is committed to expanding its product offerings to meet evolving treatment needs.

Avilex Pharma is a biotechnology company based in Copenhagen, Denmark, founded in 2012 as a spin-out from the University of Copenhagen. The company specializes in developing innovative treatments for neuropathic pain and ischemic stroke. Its research focuses on dimeric peptides that target PSD95, a postsynaptic density protein, as well as inhibitors and neuroprotectants aimed at the intracellular scaffolding protein. Avilex Pharma's mission is to enhance patient recovery and outcomes in these critical areas of healthcare, leveraging advanced drug design and pharmacology techniques developed by its founders, Professor Kristian Strømgaard and Assistant Professor Anders Bach.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of small molecule drugs aimed at treating cancer and immune/inflammatory disorders. Founded in 2005, the company focuses on designing innovative, molecular-targeted therapies. Its portfolio includes orally-active drugs such as KA2237, a dual-selective inhibitor of PI3K isoforms effective against hematological and solid tumors, and KA2507, which targets HDAC6 for tumors expressing PD-L1. By combining targeted therapy with immunotherapeutic activity, Karus Therapeutics aims to provide effective treatment options for a diverse range of cancers.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

AlloCure, Inc. is a biotechnology company focused on developing cell therapies for kidney diseases and related conditions, including organ transplants and multi-organ injuries. Founded in 2006 and based in Burlington, Massachusetts, with additional operations in Salt Lake City, Utah, and Hamburg, Germany, AlloCure is dedicated to creating off-the-shelf biological therapies to address serious health issues affecting millions globally. The company's lead product, AC607, is a biologic therapy currently in development for acute kidney injury, with potential applications for other critical illnesses. AlloCure leverages proprietary technology utilizing processed cells derived from human bone marrow, founded by esteemed scientists Dr. Christof Westenfelder and Dr. Axel Zander, who have significant expertise in developing effective treatments for kidney diseases.

Chr. Hansen is a global bioscience company that specializes in developing natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural sectors. Established in 1874, the company focuses on producing cultures, enzymes, probiotics, and natural colors that enhance the flavor, texture, shelf life, and nutritional value of various products, including foods, beverages, dietary supplements, and animal feed. With a strong emphasis on research and development, Chr. Hansen employs over 2,500 individuals across 30 countries and operates main production facilities in Denmark, France, the USA, and Germany. The company's innovative offerings cater to the health and wellness needs of consumers and contribute to sustainable practices in the industry.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Vantia Therapeutics is a pharmaceutical company based in Southampton, United Kingdom, focused on developing novel small molecule drugs to address significant unmet medical needs. Founded in 2008, the company has a strong clinical pipeline that includes VA106483, aimed at treating nocturia, a condition characterized by frequent nighttime urination, and VA111913, designed for dysmenorrhea, which involves painful menstrual cramps. Both drug candidates target conditions that affect millions of individuals and represent substantial market opportunities due to their inadequate existing treatments. Vantia's strategy involves advancing its proprietary drug candidates through Phase II clinical testing and subsequently seeking commercialization partnerships.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Adenium Biotech ApS is a Copenhagen-based biopharmaceutical company founded in 2011, specializing in the development and commercialization of novel antibiotics aimed at treating multi-drug resistant bacterial infections. The company focuses on addressing hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. Its lead product, Arenicin, is a 21-amino acid antimicrobial peptide derived from the lugworm, demonstrating strong efficacy against Gram-negative pathogens while maintaining a broad therapeutic window. Adenium Biotech operates as a semi-virtual company, relying on a small team of experts supported by an international scientific advisory board to advance its clinical development programs toward regulatory approval.

Funxional Therapeutics Ltd. is a pharmaceutical development company based in Cambridge, United Kingdom, founded in 2005. The company specializes in creating innovative therapeutic products, including BN83470, which targets respiratory conditions such as asthma, and BN83250, designed to prevent surgical adhesion formation and treat stroke. Additionally, Funxional Therapeutics is advancing FX125L, an orally available small molecule classified as a broad spectrum chemokine inhibitor. The company also has several early-stage preclinical programs aimed at addressing significant health challenges, including Alzheimer's disease, autoimmune disorders, pain, and diabetes.

Nanoference ApS develops technology that uses nano particles to deliver Sirna molecules directly to the desired part of the body. The company was founded in 2009 and is based in Aarhus, Denmark.

Archimedes Pharma Limited is a specialty pharmaceutical company based in Reading, United Kingdom, founded in 2004. The company develops and markets a range of products aimed at addressing specific medical needs, particularly in oncology and addiction treatment. Its product lineup includes Gliadel, which is used for treating high-grade gliomas; Zomorph, an oral sustained-release morphine formulation designed for cancer pain; Nozinan, an anti-emetic effective in managing nausea and vomiting in cancer patients; and Pabrinex, a vitamin formulation targeted at alcoholics undergoing acute withdrawal. Additionally, Archimedes Pharma offers Nasalfent, an intranasal fentanyl product for cancer pain relief. The company operates across the United Kingdom, France, and Germany, emphasizing its commitment to providing specialized healthcare solutions.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

EpiTherapeutics is a biotechnology company focused on developing innovative cancer therapies that leverage the science of epigenetics. Founded on research conducted by Professor Kristian Helin and his team at the Biotech Research & Innovation Centre at the University of Copenhagen, the company specializes in small-molecule therapies targeting enzymes that regulate transcription in cancer cells. EpiTherapeutics has created a library of selective small molecule inhibitors, with a particular emphasis on histone demethylases, which play a critical role in gene transcription. The company's lead compounds are currently in pre-clinical development, aimed at addressing specific types of cancer.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

AlloCure, Inc. is a biotechnology company focused on developing cell therapies for kidney diseases and related conditions, including organ transplants and multi-organ injuries. Founded in 2006 and based in Burlington, Massachusetts, with additional operations in Salt Lake City, Utah, and Hamburg, Germany, AlloCure is dedicated to creating off-the-shelf biological therapies to address serious health issues affecting millions globally. The company's lead product, AC607, is a biologic therapy currently in development for acute kidney injury, with potential applications for other critical illnesses. AlloCure leverages proprietary technology utilizing processed cells derived from human bone marrow, founded by esteemed scientists Dr. Christof Westenfelder and Dr. Axel Zander, who have significant expertise in developing effective treatments for kidney diseases.

Vantia Therapeutics is a pharmaceutical company based in Southampton, United Kingdom, focused on developing novel small molecule drugs to address significant unmet medical needs. Founded in 2008, the company has a strong clinical pipeline that includes VA106483, aimed at treating nocturia, a condition characterized by frequent nighttime urination, and VA111913, designed for dysmenorrhea, which involves painful menstrual cramps. Both drug candidates target conditions that affect millions of individuals and represent substantial market opportunities due to their inadequate existing treatments. Vantia's strategy involves advancing its proprietary drug candidates through Phase II clinical testing and subsequently seeking commercialization partnerships.